Nirmatrelvir–ritonavir
COVID-19 antiviral pills for people at high risk.
- Starts working
- Varies
- Half-life
- About 6 hours
- In use since
- 2021
- Pregnancy
- Use with caution
Overview
Paxlovid is a 5-day treatment for COVID-19 in people at high risk of severe illness. Nirmatrelvir blocks the virus; ritonavir boosts its levels by blocking liver enzymes — which is also why it interacts with many common medicines.
Conditions it's used for
How it works
Blocks the enzyme the coronavirus uses to cut its proteins into working parts.
Nirmatrelvir–ritonavir belongs to the Viral protease inhibitors. How Viral protease inhibitors work: block the viral 'scissors' enzyme, so the long protein chain the virus makes cannot be cut into working pieces.
Uses
- Mild to moderate COVID-19 in people at high risk of severe disease
Available as: co-packaged tablets.
Typical dose
- Adults
- 300 mg nirmatrelvir + 100 mg ritonavir twice a day for 5 days, started within 5 days of symptoms (lower dose in moderate kidney disease).
Typical doses for orientation only. Your prescription, the pack leaflet and local guidance take priority.
Side effects
Common
Often mild and may settle with time
- Altered taste ('Paxlovid mouth')
- Diarrhoea
- Nausea
Serious — get medical help
Uncommon, but need prompt attention
- Dangerous interactions with other medicines
- Allergic reactions
Warnings
- Every other medicine must be checked first
- Some medicines must be paused, others mean Paxlovid can't be used
Interactions
- Simvastatin, colchicine, some antiarrhythmics and sedatives — contraindicated
- Tacrolimus, ciclosporin — dangerous rises
- DOACs, many others — dose changes
Other medicines in the atlas that need care with Nirmatrelvir–ritonavir, grouped by the reason:
Dangerous rise in drug levelsMajorWith Ciclosporin, Colchicine, Fentanyl, Midazolam, Simvastatin and 3 more
A strong CYP3A4 inhibitor blocks breakdown of a drug where higher levels are hazardous (e.g. simvastatin — muscle breakdown; colchicine — fatal toxicity; tacrolimus — kidney damage; fentanyl or midazolam — breathing suppression).
What's usually done: Usually contraindicated or needs a planned pause or major dose change. Always check with a pharmacist.
More anticoagulant effectMajorWith Apixaban, Dabigatran, Edoxaban, Rivaroxaban
Combined P-glycoprotein and strong CYP3A4 inhibition can raise apixaban or rivaroxaban exposure and increase bleeding.
What's usually done: Follow the apixaban or rivaroxaban label: avoid or reduce the DOAC dose as directed with strong dual inhibitors.
Colchicine toxicityMajorWith Colchicine
Transporter inhibition can raise colchicine exposure; toxicity may cause severe diarrhoea, muscle injury, bone-marrow suppression or organ failure.
What's usually done: Avoid many combinations, especially with kidney or liver disease. Use a lower dose only under specialist advice.
Digoxin toxicityMajorWith Digoxin
P-glycoprotein inhibition can raise digoxin levels, increasing the risk of nausea, visual changes, confusion and dangerous heart rhythms.
What's usually done: Check the digoxin level and kidney function; a dose reduction may be needed.
Raised drug levelsModerateWith Abiraterone, Alfuzosin, Alprazolam, Amlodipine, Apremilast and 55 more
Blocking CYP3A4 increases levels of this medicine, so side effects become more likely.
What's usually done: A dose reduction, alternative or extra monitoring may be needed.
Higher rhythm riskModerateWith Amiodarone, Amisulpride, Amitriptyline, Artemether–lumefantrine, Azithromycin and 38 more
Some CYP3A4 inhibitors raise concentrations of QT-prolonging medicines, adding to the risk of torsades and fainting.
What's usually done: Avoid high-risk combinations where possible; review the specific medicine and consider ECG monitoring.
Low blood sugarModerateWith Glibenclamide, Gliclazide, Glimepiride, Glipizide
Some CYP3A4 inhibitors increase exposure to sulfonylureas, making hypoglycaemia more likely.
What's usually done: Check glucose more often and review the diabetes dose when the inhibitor starts or stops.
INR may riseModerateWith Warfarin
Some CYP3A4 inhibitors can slow warfarin metabolism and increase anticoagulant effect.
What's usually done: Check INR soon after starting or stopping the inhibitor and adjust warfarin only through the anticoagulation service.
Pregnancy and breastfeeding
Use with caution
Can be used if benefits outweigh risks; limited data.
Breastfeeding advice can differ from pregnancy advice — check with a pharmacist, or the LactMed database.
Brand names
- United States
- Paxlovid
- United Kingdom
- Paxlovid
- Australia
- Paxlovid
Examples only; many generic versions exist. The same brand name can mean different products in different countries.
History
2021
Emergency authorisation in the US (December).
2023
Full FDA approval.
Rebound — symptoms returning a few days after finishing — happens in a minority of people, with or without Paxlovid.
Common questions
Can I take it if I'm on a statin?
Some statins are paused during treatment; others need no change. A pharmacist can check your list.
Do I need a prescription for Nirmatrelvir–ritonavir?
Yes — Nirmatrelvir–ritonavir is prescription-only in most countries.
Can I take Nirmatrelvir–ritonavir during pregnancy?
Use with caution. Can be used if benefits outweigh risks; limited data. Always check with a doctor or midwife.
Related medicines
Remdesivir
IV antiviral for COVID-19.
RxRNA polymerase inhibitorsOseltamivir
Flu treatment best started within 48 hours.
RxWHONeuraminidase inhibitorsDexamethasone
Long-acting potent steroid — the first drug proven to cut COVID-19 deaths.
RxWHOCorticosteroidsDarunavir
Potent boosted protease inhibitor for HIV with resistance.
RxViral protease inhibitorsLopinavir-ritonavir
Boosted protease inhibitor for HIV, mostly used as a second-line option.
RxWHOViral protease inhibitors
Sources and official information
Entry last reviewed October 2026. Compiled from WHO, NHS, FDA/DailyMed, BNF and national formulary information. How we write entries.